MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21873/anticanres.16966

Медицинская библиотека · Anticancer research · 2024

Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.

Furubayashi Nobuki, Minato Akinori, Tomoda Toshihisa, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Haraguchi Yusuke, Koga Toshiki, Harada Kenichi, Kuroiwa Kentaro, Fujimoto Naohiro, Nakamura Motonobu, Uro-Oncology Group in Kyushu (UROKYU)

СтатьяПеревод в очереди

Аннотация

BACKGROUND/AIM: The association between clinical outcomes and posttreatment changes in the neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-eosinophil ratio (NER) in patients receiving avelumab maintenance therapy for advanced urothelial carcinoma (UC) is unclear.

PATIENTS AND

METHODS

We retrospectively analyzed data from advanced UC patients who received avelumab and had not progressed with first-line platinum-based chemotherapy. The association between the changes in NLR and NER from pretreatment to week 6 of avelumab treatment and therapeutic efficacy was evaluated.

RESULTS

Thirty-two patients were enrolled in this study (male, n=25; female, n=7; median age, 71 years). At six weeks, 19 patients (59.4%) had a decreased NLR and 18 patients (56.3%) had a decreased NER. When the change in NER from pretreatment to six weeks was compared, there was a significant decrease in responders (without progressive disease) (p=0.008); however, there was no significant decrease in non-responders (progressive disease) (p=0.855). The NLR showed no significant change in either group (p=0.099, 0.358). When patients were compared according to the change in the NLR at six weeks, progression-free survival (PFS) and overall survival (OS) did not differ between the decreased NLR and increased NLR groups (p=0.116, 0.256). When patients were compared according to the change in the NER, the decreased and increased groups showed significant differences in PFS and OS (p<0.001, 0.030).

CONCLUSION

In the present real-world study, the responders showed a significantly decreased NER at six weeks. This was associated with improved PFS and OS in patients with advanced UC.

Для цитирования: Furubayashi Nobuki, Minato Akinori, Tomoda Toshihisa, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Haraguchi Yusuke, Koga Toshiki, Harada Kenichi, Kuroiwa Kentaro, Fujimoto Naohiro, Nakamura Motonobu, Uro-Oncology Group in Kyushu (UROKYU). Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.. Anticancer research. 2024. DOI: 10.21873/anticanres.16966.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.